Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANCNNYSE:ANVSNASDAQ:APVONASDAQ:AVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANCNAnchiano Therapeutics$1.36-0.5%$21.77$0.51▼$10.55$10.11M0.933.15 million shs40,260 shsANVSAnnovis Bio$2.34-2.5%$1.60$1.11▼$17.88$45.60M1.46720,704 shs240,186 shsAPVOAptevo Therapeutics$4.75+1.1%$1.01$4.30▼$658.60$1.92M6.0672,359 shs70,594 shsAVTXAvalo Therapeutics$3.95+6.2%$5.07$3.39▼$16.00$42.77M0.8754,250 shs57,176 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANCNAnchiano Therapeutics-2.14%-0.72%+2.24%-15.43%+50.75%ANVSAnnovis Bio-0.83%+17.65%+63.82%+31.87%-60.33%APVOAptevo Therapeutics+2.17%-21.67%-58.48%-93.85%-99.98%AVTXAvalo Therapeutics+3.62%-4.86%-25.60%-49.11%-69.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANVSAnnovis Bio1.6403 of 5 stars3.51.00.00.01.11.70.6APVOAptevo Therapeutics2.5723 of 5 stars3.55.00.00.02.10.00.6AVTXAvalo Therapeutics2.824 of 5 stars3.43.00.00.02.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANCNAnchiano Therapeutics 0.00N/AN/AN/AANVSAnnovis Bio 3.00Buy$34.751,385.04% UpsideAPVOAptevo Therapeutics 3.00Buy$219,040.004,611,268.42% UpsideAVTXAvalo Therapeutics 2.83Moderate Buy$33.00735.44% UpsideCurrent Analyst Ratings BreakdownLatest ANCN, ANVS, APVO, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.002/28/2025AVTXAvalo TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANCNAnchiano TherapeuticsN/AN/AN/AN/A$2.01 per shareN/AANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AAPVOAptevo Therapeutics$3.11M0.62N/AN/A$3.26 per share1.46AVTXAvalo Therapeutics$441K96.99N/AN/A$9.11 per share0.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANCNAnchiano Therapeutics-$27.12M-$3.469.08N/AN/AN/A36.08%27.40%N/AANVSAnnovis Bio-$56.20M-$2.16N/AN/AN/AN/AN/A-311.00%8/13/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-488.93%-152.51%8/14/2025 (Estimated)AVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)Latest ANCN, ANVS, APVO, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANCNAnchiano TherapeuticsN/AN/AN/AN/AN/AANVSAnnovis BioN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANCNAnchiano TherapeuticsN/A3.253.25ANVSAnnovis BioN/A2.662.66APVOAptevo TherapeuticsN/A1.721.72AVTXAvalo TherapeuticsN/A1.421.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANCNAnchiano Therapeutics9.05%ANVSAnnovis Bio15.83%APVOAptevo Therapeutics8.06%AVTXAvalo Therapeutics87.06%Insider OwnershipCompanyInsider OwnershipANCNAnchiano Therapeutics6.88%ANVSAnnovis Bio20.80%APVOAptevo Therapeutics0.01%AVTXAvalo Therapeutics3.03%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANCNAnchiano Therapeutics167.42 millionN/ANot OptionableANVSAnnovis Bio319.49 million9.64 millionOptionableAPVOAptevo Therapeutics50405,0001.46 millionNot OptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableANCN, ANVS, APVO, and AVTX HeadlinesRecent News About These CompaniesAvalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis SuppurativaMay 13, 2025 | nasdaq.comAVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly EarningsMay 13, 2025 | nasdaq.comTango dances away from preclinical work to extend cash runway, while Avalo lays out spending optionsMay 12, 2025 | fiercebiotech.comAvalo Therapeutics: Avalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 12, 2025 | finanznachrichten.deAvalo Reports First Quarter 2025 Financial Results and Recent Business UpdatesMay 12, 2025 | globenewswire.comDeep Track Capital LP Sells 100,000 Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 9, 2025 | marketbeat.comAvalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on MondayMay 7, 2025 | marketbeat.comBVF Inc. IL Grows Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 6, 2025 | marketbeat.comWhy Avalo Therapeutics, Inc.’s (AVTX) Stock Is Down 5.56%May 5, 2025 | aaii.comAllostery Investments LP Buys Shares of 73,314 Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 4, 2025 | marketbeat.comGeode Capital Management LLC Increases Position in Avalo Therapeutics, Inc. (NASDAQ:AVTX)May 4, 2025 | marketbeat.comWhy Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 5.82%May 2, 2025 | aaii.comAvalo Therapeutics to Participate in The Citizens Life Sciences ConferenceApril 30, 2025 | globenewswire.comSeven new option listings and one option delisting on April 16thApril 17, 2025 | markets.businessinsider.comAvalo Therapeutics Reports 2024 Financial ResultsApril 16, 2025 | tipranks.comWhy Avalo Therapeutics, Inc.’s (AVTX) Stock Is Down 13.79%April 8, 2025 | aaii.comWhy Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 11.93%March 26, 2025 | aaii.comAvalo Therapeutics initiated with a Buy at JefferiesMarch 26, 2025 | markets.businessinsider.comAvalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardMarch 26, 2025 | globenewswire.comStifel initiates Avalo Therapeutics stock with a Buy ratingMarch 26, 2025 | investing.comStifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationMarch 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANCN, ANVS, APVO, and AVTX Company DescriptionsAnchiano Therapeutics NASDAQ:ANCNAnchiano Therapeutics Ltd., a preclinical biotechnology company, discovers, develops, and commercializes small molecule anti-cancer therapies. It primarily develops Pan-RAS Program that identifies novel indene-based small molecules that exhibit potent and selective inhibition of activated RAS signaling regardless of isoform or mutation; and PDE10/Ã-catenin program, which identifies small molecules that selectively and potently inhibit PDE10 and suppress Wnt/APC/Ã-catenin signaling in preclinical models. Anchiano Therapeutics Ltd. has collaboration and license agreement with ADT Pharmaceuticals, LLC to research and develop programs related to the pan-RAS and PDE10/Ã-catenin programs. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd. in July 2018. Anchiano Therapeutics Ltd. was founded in 2004 and is headquartered in Cambridge, Massachusetts.Annovis Bio NYSE:ANVS$2.34 -0.06 (-2.50%) Closing price 03:59 PM EasternExtended Trading$2.39 +0.05 (+2.14%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Aptevo Therapeutics NASDAQ:APVO$4.75 +0.05 (+1.06%) Closing price 04:00 PM EasternExtended Trading$4.68 -0.07 (-1.47%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Avalo Therapeutics NASDAQ:AVTX$3.95 +0.23 (+6.18%) Closing price 04:00 PM EasternExtended Trading$4.18 +0.23 (+5.70%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
